What we do

For more than 45 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Featured

Press Release, Product 26 December 2024

Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US Press Release, Product 26 December 2024 Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US
Hikma launches Indomethacin Suppositories in the US Press Release, Product 20 December 2024 Hikma launches Indomethacin Suppositories in the US
Hikma acquires the rights to a portfolio of Takeda brands for the MENA region Press Release, Product 19 December 2024 Hikma acquires the rights to a portfolio of Takeda brands for the MENA region
Hikma and Richter announce FDA submission acceptance for Denosumab biosimilar products Press Release, Product 12 December 2024 Hikma and Richter announce FDA submission acceptance for Denosumab biosimilar products